Astrazeneca

This study tests two experimental vaccines, AZD4117 and AZD5315, designed to protect against certain bird flu strains (H5N1 and H7N9). About 405 healthy adults will receive either a vaccine or a placebo to check for side effects and measure immune response. The goal is to find a …

This study tests a new oral drug, camizestrant, combined with palbociclib against the standard anastrozole plus palbociclib for people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1,370 participants will be fol…

This study tests whether adding selumetinib to standard chemotherapy (docetaxel) helps people with a specific genetic form of advanced lung cancer (KRAS mutation). About 510 adults whose cancer worsened after first treatment will receive either the combo or a placebo plus chemo. …

This early-phase study tests a new drug called AZD9833, alone or with other treatments, in 396 women with advanced ER-positive, HER2-negative breast cancer. The main goals are to check safety and find the right dose. Researchers also look at how well the drug shrinks tumors. Part…

This study tests a new medicine called AZD0780 in adults with a genetic condition that causes very high cholesterol (heterozygous familial hypercholesterolemia). The goal is to see if it safely lowers 'bad' LDL cholesterol more than a placebo. About 473 participants will take eit…

This study tests a combination of two immune-boosting drugs (durvalumab and tremelimumab) as the first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink…

This study follows about 551 people with systemic lupus erythematosus (SLE) who are starting a new treatment called anifrolumab. Researchers want to see how well the drug controls disease activity and improves quality of life in routine medical practice, not just in a controlled …

This study tests a new drug called AZD5305 given together with standard hormone therapies for men whose prostate cancer has spread. The main goals are to check safety, find the right dose, and see early signs of whether the combination helps control the cancer. About 174 men with…

This study is for people with advanced non-small cell lung cancer whose disease has gotten worse after treatment with immunotherapy (anti-PD-1/PD-L1 drugs). It tests several different drug combinations, chosen based on the specific biomarkers (genetic markers) found in each perso…

This study tests whether the drug olaparib can help keep advanced ovarian cancer from coming back after initial chemotherapy. It includes 366 women with a specific type of ovarian cancer (high-grade serous or endometrioid) that does not have a BRCA gene mutation. Participants rec…

This study looks at whether two different doses of Nexium can safely keep the esophagus healed in children aged 1 to 11 who have erosive esophagitis. About 53 kids will take part, first in an 8-week healing phase, then a 16-week maintenance phase. The main goal is to check if the…

This study tests whether adding capivasertib to standard chemotherapy (paclitaxel) helps people with advanced triple-negative breast cancer live longer. About 923 participants receive either the combination or a placebo plus chemotherapy. The goal is to see if the new drug improv…

This study tests whether adding another drug (oleclumab or monalizumab) to the standard immunotherapy durvalumab can help people with stage III lung cancer that cannot be removed by surgery. About 1,050 adults who finished chemotherapy and radiation without their cancer getting w…

This study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple-negative breast cancer in people who haven't had prior treatment for advanced disease. About 243 women with advanced…

This study looks at how long 151 adults with chronic lymphocytic leukemia (CLL) in Italy stay on the drug acalabrutinib (Calquence) and why they might stop. Researchers are collecting data from routine care to see how the drug works outside of clinical trials. The goal is to bett…

This study tests several different drug combinations in people with advanced bladder cancer that has gotten worse after earlier treatments. The goal is to find out which combinations are safe and might work best based on the specific genetic changes in each person's tumor. About …

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors or stop them from growing. About 477 adults with bladder, bile duct, cervical, endometrial, ovar…

This study is for people with a type of liver cancer that cannot be removed by surgery. It tests a treatment plan that starts with a targeted radiation procedure (TARE) using tiny glass beads, followed by two drugs (durvalumab and bevacizumab) that help the immune system fight th…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine and cisplatin) before surgery, followed by durvalumab alone after surgery, helps people with muscle-invasive bladder cancer. About 1,000 participants are involved. The goal is …

This study tests the drug selumetinib in adults with neurofibromatosis type 1 (NF1) who have painful, inoperable nerve tumors called plexiform neurofibromas. About 145 participants worldwide will receive either selumetinib or a placebo to see if the drug can shrink tumors and red…

This study tests whether adding two new drugs (datopotamab deruxtecan and rilvegostomig) after surgery can keep stage I lung cancer from coming back. It is for people whose tumors have certain high-risk features or signs of cancer DNA in the blood. Participants will receive eithe…

This early-stage study tests a new drug combination (ceralasertib plus durvalumab) in Chinese patients with advanced solid tumours that have stopped responding to standard treatments. The main goal is to check the safety and side effects of the combination, and to see how the dru…

This study tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with a certain type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) whose disease has gotten worse after initial osimertinib treatment. About 98 participants wi…

This study tests an experimental drug called tezepelumab in 368 adults and teens (ages 12-80) with eosinophilic esophagitis, a condition where allergy cells build up in the esophagus and make swallowing painful or difficult. Participants receive either the drug or a placebo as a …

This study tests whether adding the immunotherapy drugs durvalumab and tremelimumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 1,200 participants who have not had prior chemotherapy will receive either chemo alone or chemo plus the immun…

This study tests whether anifrolumab, an injected drug, can improve symptoms of systemic sclerosis (scleroderma) better than a placebo. About 314 adults aged 18-70 with early-stage disease (less than 6 years) will participate. The main goal is to see if the drug helps skin thicke…

This study tested adding the immunotherapy drug durvalumab to standard chemotherapy for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. About 810 participants received either durvalumab plus chemo or a placebo plus chemo. The results showed…

This study looks at how taking the drug selumetinib with a low-fat meal affects stomach side effects and drug levels in adolescents (ages 12 to under 18) with neurofibromatosis type 1 (NF1) who have inoperable plexiform neurofibromas. The goal is to find the best way to take the …

This study tests whether adding savolitinib to the standard drug osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR mutation-positive and MET amplified) that has worsened despite osimertinib treatment. About 30 adults …

This study tests whether adding olaparib to standard abiraterone therapy can delay cancer growth or death in men with metastatic castration-resistant prostate cancer who have not yet had chemotherapy. About 110 participants receive either olaparib plus abiraterone or a placebo pl…

This study is testing a combination of two drugs, MEDI4736 (which helps the immune system fight cancer) and olaparib (which targets cancer cells with DNA repair problems), in people with advanced solid tumors like ovarian, breast, lung, and stomach cancers. The goal is to see if …

This study looks at how well ravulizumab works for people with paroxysmal nocturnal hemoglobinuria (PNH) in everyday medical practice in Poland. About 64 adults are being followed to see changes in blood markers and how many need blood transfusions. The goal is to understand the …

This study aimed to test new anticancer drugs, chosen based on specific biomarkers, for people with advanced or recurrent ovarian cancer. It was designed to check safety and early effectiveness, but was withdrawn before enrolling any participants. No results are available.

This study tests whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus chemotherapy works better than the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-small cell lung cancer that has specific gene mutations (S…

This study tests a drug called AZD0901 in 33 adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The cancer must have a specific protein (Claudin18.2). The goal is to see if the drug can shrink tumors and how safe it is. Pa…

This study tested whether adding the immunotherapy drugs durvalumab and tremelimumab to standard chemotherapy helps people with advanced non-small cell lung cancer live longer without their disease getting worse. About 1,200 adults with a specific type of lung cancer that had spr…

This study tests a new combination of two drugs (ceralasertib and durvalumab) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has worsened after prior treatments. About 594 participants will be enrolled to see if the combo helps t…

This phase 3 study compares a new drug, Dato-DXd, with standard chemotherapy in 732 people whose HR-positive, HER2-negative breast cancer has spread and is no longer responding to hormone therapy. Participants have had one or two prior chemotherapies. The goal is to see if Dato-D…

This study tests whether adding immunotherapy drugs (durvalumab with or without bevacizumab) to a standard procedure called TACE can help control liver cancer that has not spread outside the liver. About 724 adults with liver cancer that cannot be surgically removed are participa…

This study tests whether taking olaparib daily after initial chemotherapy can delay cancer growth in people with advanced ovarian cancer who have a BRCA gene mutation. About 450 participants who responded well to first-line platinum chemo will receive either olaparib or a placebo…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug works by attaching to cancer cells and blocking their growth. About 119 participa…

This study follows 254 adults with extensive-stage small cell lung cancer, a fast-growing cancer, to see how well durvalumab (an immunotherapy) works with standard chemotherapy in everyday medical practice. The main goal is to measure how long patients stay on treatment, and rese…

This early-stage study tests the safety and effectiveness of selumetinib, a drug that blocks a key cancer growth signal, in 32 Chinese children and adults with neurofibromatosis type 1 (NF1) who have inoperable plexiform neurofibromas (nerve tumors). Participants take the drug by…

This study tests a new drug (AZD0171) combined with two other treatments (durvalumab and chemotherapy) in people with advanced pancreatic cancer that has spread. The goal is to see if this combination is safe and helps control the disease longer. About 126 participants will recei…

This study tests whether adding durvalumab to standard chemotherapy helps people with advanced biliary tract cancer (a rare cancer of the bile ducts or gallbladder). About 142 participants will receive the combination as their first treatment. The goal is to see if it improves su…

This early-stage study tests an experimental drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal is to find a safe dose and see how the body handles the drugs. Participants must …

This study tests whether adding the drug rilvegostomig to standard chemotherapy can help prevent biliary tract cancer from returning after surgery. About 757 adults who had their cancer completely removed will receive either rilvegostomig plus chemo or a placebo plus chemo. The m…

This study tests a new medicine called AZD0780 to see if it safely lowers 'bad' LDL cholesterol in adults who already have heart disease or are at high risk. About 3100 participants will take either the drug or a placebo for 52 weeks, without knowing which they receive. The main …

This study tests a new drug, Dato-DXd, against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. About 644 participants will be randomly assigned to receive either Dato-DXd or one of several chemotherapy options. The go…

This phase 3 study tests whether adding the drug durvalumab to standard chemotherapy (FLOT) before and after surgery can help people with resectable stomach or gastroesophageal junction cancer live longer without the disease getting worse. About 957 participants receive either du…

This study follows 152 adults with COPD who start taking a three-in-one inhaler (budesonide/glycopyrronium/formoterol). Researchers measure changes in symptoms, quality of life, and lung attacks over 6 months. The goal is to see how well the treatment works in everyday life, not …

This early-stage study tests a new drug called ceralasertib, given as a pill, together with other cancer treatments (chemotherapy or targeted drugs) in adults with advanced solid tumors that have stopped responding to standard care. The main goals are to check safety, find the be…

This study tested whether a higher dose (500 mg) of the hormone therapy fulvestrant works better than the standard dose (250 mg) in postmenopausal women with advanced breast cancer that had worsened after previous hormone treatments. The trial involved 736 participants and measur…

This study tests whether adding savolitinib to osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutated, MET-positive) whose cancer has worsened despite osimertinib treatment. About 345 adults will be randomly assigned to receive either the drug comb…

This study tests whether a combination of two drugs, savolitinib and durvalumab, works better than the standard drug sunitinib for people with a rare type of kidney cancer called papillary renal cell carcinoma that has spread. The cancer must have a specific genetic change (MET-d…

This study tests whether adding the drug capivasertib to standard hormone therapy (abiraterone and ADT) can slow the growth of prostate cancer that has spread and has a specific genetic change (PTEN deficiency). About 1,000 men with this type of cancer will receive either the com…

This study tested whether the drug durvalumab can help people with advanced, inoperable lung cancer (Stage III) keep their cancer from growing after they finish chemotherapy and radiation. About 400 adults who had not gotten worse after initial treatment received either durvaluma…

This study tested whether the immunotherapy drug durvalumab works better than standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 669 adults with stage IV lung cancer and no specifi…

This study looks at whether the drug olaparib works better than standard treatments (enzalutamide or abiraterone) for Chinese men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. All participants have a BRCA1 or BRCA2 gene mutation. Th…

This study tests whether adding the experimental drug monalizumab to the standard drug cetuximab helps people with advanced head and neck cancer live longer. About 370 adults whose cancer returned or spread after prior treatments, including immunotherapy, will receive either the …

This study tests whether adding olaparib to durvalumab can keep stage IV non-small cell lung cancer from progressing longer than durvalumab alone. About 400 adults whose cancer did not worsen after initial chemotherapy plus durvalumab will receive either the combination or durval…

This study tests the drug osimertinib in people with non-small cell lung cancer that has certain uncommon gene changes (EGFR mutations). Participants take the pill after their tumor is completely removed by surgery. The goal is to see if the drug helps keep the cancer from coming…

This study tests a new combination of drugs (datopotamab deruxtecan, durvalumab, and carboplatin) against the current standard treatment for advanced non-small cell lung cancer that doesn't have certain gene changes. About 1,350 adults with stage IIIB, IIIC, or IV lung cancer wil…

This study tests an experimental oral drug, AZD0780, to see if it safely lowers LDL (bad) cholesterol in people with dyslipidaemia. About 432 adults in China will take the drug or a placebo daily for up to 52 weeks. The goal is to measure how well the drug reduces cholesterol lev…

This study tests whether a new combination of drugs (datopotamab deruxtecan plus durvalumab) works better than the current standard treatment for people with triple-negative or hormone receptor-low breast cancer that hasn't spread. About 1,900 adults with stage II or III breast c…

This study tests whether adding an experimental drug (AZD2811) to the immunotherapy durvalumab can help keep extensive-stage small-cell lung cancer from growing after initial treatment. About 31 adults with this aggressive cancer will receive the combination as maintenance therap…

This study tests a drug called eplontersen in Chinese adults with a heart condition caused by a faulty protein (transthyretin amyloid cardiomyopathy). The goal is to see if the drug safely lowers that protein and improves heart health. About 64 participants will receive either ep…

This study tests whether a daily pill called AZD9291 (osimertinib) can prevent lung cancer from returning after surgery in people with a specific gene mutation (EGFR). About 682 adults with stage IB to IIIA non-small cell lung cancer took either the drug or a placebo for up to 3 …

This study tests whether adding olaparib to standard abiraterone therapy can help men with a certain type of advanced prostate cancer that no longer responds to hormone therapy. About 895 men will receive either the combination or a placebo plus abiraterone. The main goal is to s…

This study tests whether a combination of two experimental drugs (AZD9550 and AZD6234) given as weekly shots can help people with obesity or overweight lose more weight than a placebo or either drug alone. About 377 adults aged 18-75 with a BMI of 30 or higher (or 27 with a weigh…

This study tests whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) after standard chemoradiation can help people with limited-stage small cell lung cancer live longer without their cancer growing. About 730 participants who completed initial treatme…

This study tests a new granule (sprinkle) form of the drug selumetinib in 36 children aged 1 to under 7 years who have neurofibromatosis type 1 (NF1) with painful, inoperable tumors called plexiform neurofibromas. The goal is to find the right dose, check safety, and see if the d…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in about 500 people with advanced HER2-positive breast cancer that has worsened after prior treatments. Some participants have brain metastases, others do not. The goal is to see how well the drug shrinks tumors and de…

This study tests whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or radiation can help people with stage IIB-IIIB non-small cell lung cancer. After initial treatment, participants either have surgery followed by more durvalumab, or…

This study tests whether a new two-drug combination (zibotentan plus dapagliflozin) works better than dapagliflozin alone at slowing kidney function loss in people with chronic kidney disease and high protein in their urine. About 1,800 adults with moderate to severe kidney disea…

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced non-small cell lung cancer with a specific EGFR mutation. About 60 adults who have not had prior treatment for their advanced or metastatic disease will receive the dru…

This study offers continued treatment with the drug osimertinib to cancer patients who have already completed a previous study and are still benefiting from the drug. The main goal is to monitor safety and side effects. About 37 participants are expected to enroll.

This study follows 416 people with severe asthma that other treatments cannot control. Researchers are checking how safe and effective Tezspire is over long-term use, looking for side effects like serious infections or allergic reactions. The goal is to confirm the drug's safety …

This study tests a drug called acalabrutinib in Chinese adults whose B-cell cancers (like mantle cell lymphoma or chronic lymphocytic leukemia) have come back or stopped responding to treatment. The goal is to see if the drug is safe and helps shrink or control the cancer. About …

This study tests whether taking osimertinib daily after standard chemoradiation can delay cancer growth in people with stage III EGFR-mutated non-small cell lung cancer that hasn't spread. About 216 adults with this specific genetic type of lung cancer will receive either osimert…

This study tests a combination of three drugs (acalabrutinib, venetoclax, and rituximab) in people with untreated mantle cell lymphoma, a rare blood cancer. The goal is to see if the treatment can make the cancer undetectable in the blood and keep it under control. Participants w…

This study tests whether a new drug called volrustomig, combined with chemotherapy, works better than the standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has spread. About 1,200 adults whose tumors have low levels of a protei…

This study tested adding the immunotherapy drugs durvalumab (with or without tremelimumab) to standard chemotherapy for people with extensive-stage small-cell lung cancer, a fast-growing cancer that has spread. About 987 participants received either chemo alone or chemo plus the …

This study tests whether a combination of two drugs, durvalumab and olaparib, can help control advanced bladder cancer in people who cannot receive standard platinum-based chemotherapy. About 154 participants with stage IV bladder cancer that cannot be removed by surgery will rec…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs shri…

This study tests if the drug benralizumab can help people with severe eosinophilic asthma safely reduce their daily controller medications while still keeping their asthma under control. About 504 patients in China will try to step down their usual asthma treatments under medical…

This study tests whether adding the drug durvalumab to standard chemotherapy and radiation can help people with advanced esophageal cancer that cannot be removed by surgery. About 640 adults with this type of cancer will receive either durvalumab or a placebo alongside their canc…

This study tests a new drug called AZD9829 in people with blood cancers that have a specific marker (CD123) and have not responded to other treatments. The main goals are to find a safe dose and check for side effects. About 56 adults will take part, receiving the drug alone or w…

This study compares two drug combinations for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 600 participants will receive either acalabrutinib plus venetoclax or venetoclax plus obinutuzumab. The goal is to see which combination better co…

This study tests a drug called tozorakimab in people with COPD who have had flare-ups in the past. The goal is to see if it can reduce the number of severe breathing attacks over time. About 1,700 adults who finished earlier studies will take either the drug or a placebo for long…

This study tests a drug called trastuzumab deruxtecan (T-DXd) alone or with other medicines in people with advanced solid tumors that have a specific marker (HER2). The goal is to see if the drug can shrink tumors and control the disease. About 127 adults with tumors that cannot …

This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. It involves 532 adults with stage IIIB, IIIC, or IV disease who have not had prior therapy. The goal is to me…

This study tests whether adding the drug durvalumab to standard chemoradiation helps people with stage III lung cancer that cannot be removed by surgery. About 328 participants received either durvalumab or a placebo alongside their usual treatment. The main goal is to see if the…

This study tests whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) works better than standard chemotherapy for people with advanced lung cancer who have not had prior treatment. About 950 adults with a specific type of non-small cell lung cancer are t…

This study looks at whether a special care plan, called a transition bundle, can help people with COPD avoid serious health declines after a flare-up. About 1,368 patients from 36 hospitals will take part. Hospitals are randomly assigned to either use the new care plan or continu…

This phase 3 study tested two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. Over 1,300 participants received either the drug combination, durvalumab alone, or the standard drug soraf…

This study looks at how safe and effective the drug selumetinib is for children aged 3 to 16 with a condition called neurofibromatosis type 1 (NF1) that causes painful, non-cancerous tumors that cannot be removed by surgery. About 80 to 100 children in China will take the drug an…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy, followed by maintenance durvalumab with or without the targeted drug olaparib, can help people with newly diagnosed advanced or recurrent endometrial cancer live longer without their cance…

This study tests a new treatment called AZD5851 for adults with advanced or recurrent liver cancer. The treatment uses specially engineered immune cells (CAR-T cells) to target a protein called GPC3 found on cancer cells. The main goals are to check if the treatment is safe and t…

This study tests whether adding the drugs durvalumab (alone or with bevacizumab) after surgery or ablation can prevent liver cancer from returning in patients at high risk. About 900 adults who have had their liver cancer completely removed or destroyed are randomly assigned to r…

This early-phase study tested the safety and tolerability of an experimental drug called AZD6244, given as a capsule, in 58 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to identify side effects and determine how the drug …

This study tests a drug called benralizumab in 75 adults with severe asthma that is not well controlled by standard inhalers. The goal is to see if the drug can reduce airway inflammation and improve lung structure and function over 48 weeks. Participants continue their usual ast…

This study offers continued access to the drug olaparib for people with ovarian or breast cancer who were already benefiting from it in a previous clinical trial. About 185 participants will keep receiving treatment as long as their doctor believes it helps them. The main goal is…

This study tests two new treatments (volrustomig alone or with casdatifan) against the current standard therapy for people with advanced clear cell kidney cancer that has not been treated before. About 1,116 participants worldwide will take part. The goal is to see if the new com…

This study tests whether giving the targeted drug osimertinib before and after standard chemoradiation helps adults with a specific type of stage III lung cancer (EGFR mutation-positive) that cannot be removed by surgery. About 76 participants will receive osimertinib first, then…

This phase 2 study tested a new oral drug, AZD9833, against a standard injected drug, fulvestrant, in 240 women with advanced ER-positive HER2-negative breast cancer. The main goal was to see how long the cancer stayed under control. Results from one dose group were limited becau…

This study tests two experimental treatments (Dato-DXd alone or with durvalumab) against standard therapy for people with triple-negative breast cancer who still have cancer cells in the breast or lymph nodes after surgery and chemotherapy. About 1,174 participants will be random…

This study tests a drug called volrustomig in 37 women with advanced cervical cancer that hasn't spread to other organs. Participants have already completed standard chemotherapy and radiation. The goal is to see if volrustomig can help keep the cancer from coming back or growing…

This study tests an injected drug called benralizumab in people with hypereosinophilic syndrome (HES), a rare condition where too many white blood cells cause organ damage. About 134 participants aged 12 and older will receive either benralizumab or a placebo every 4 weeks for 24…

This study tested whether adding the drug olaparib to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced ovarian cancer live longer without their disease getting worse. It included 162 patients whose cancer had previously responded to platinum-based tre…

This study tests a combination of two drugs—BCG (a standard immunotherapy) and durvalumab (a newer immunotherapy)—in 100 adults with high-risk non-muscle-invasive bladder cancer who have not received BCG before. The goal is to see if the combination is safe and effective at contr…

This early-stage study tests a new medicine called AZD0780 in 40 healthy adults who have high LDL ("bad") cholesterol. The main goal is to see if the drug safely lowers cholesterol levels compared to a placebo. Participants will take the drug or placebo by mouth and be monitored …

This study tests an experimental drug called AZD2936 in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not responded to other treatments. The drug is a bispecific antibody designed to block two proteins (TIGIT and PD-1) that help cancer hide from t…

This study tests a drug called anifrolumab in 359 adults with active lupus nephritis, a serious kidney complication of lupus. The goal is to see if the drug can help the kidneys work better and reduce the need for steroids. Participants receive either the drug or a placebo, and r…

This study tests whether a newer targeted drug, trastuzumab deruxtecan (T-DXd), given alone or with another drug (pertuzumab), works better than the current standard treatment for people with HER2-positive breast cancer that has spread. About 1,157 adults with advanced or metasta…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other cancer medicines in people with HER2-positive breast cancer that has spread. The goal is to find safe doses and see if the combination shrinks tumors. About 245 adults with advanced or metastatic di…

This study tests whether adding a second drug (savolitinib) to the standard drug osimertinib can shrink tumors in people with a specific type of advanced lung cancer (EGFR-mutant, MET-positive) that has stopped responding to osimertinib alone. About 367 adults whose cancer worsen…

This study tests a combination of two drugs, savolitinib and durvalumab, in Chinese adults with a certain type of advanced lung cancer (non-small cell lung cancer with MET gene changes) that has not responded to standard treatments. The goal is to see if the combination can shrin…

This study tests an experimental drug called AZD6234 to see if it helps people with overweight or obesity and type 2 diabetes lose more weight when added to their current diabetes medication. About 69 adults will receive either AZD6234 or a placebo for 26 weeks. The main goal is …

This study tests a new drug, trastuzumab deruxtecan (T-DXd), against standard chemotherapy in 866 people with a common type of advanced breast cancer (HER2-low, hormone receptor-positive) that stopped responding to hormone therapy. The goal is to see if T-DXd can slow cancer grow…

This early-stage study tests a new medicine called AZD1705 in about 98 adults with high cholesterol. The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo as a shot, and researchers monitor side effects and …

This study tests whether adding baxdrostat to the standard drug dapagliflozin can better slow chronic kidney disease (CKD) in adults with high blood pressure. About 2,500 participants will receive either the combination or dapagliflozin alone for 24 months. The main goal is to se…

This early-stage study tests the safety and best dose of a drug called AZD9291 (osimertinib) combined with either AZD6094 or selumetinib in people with advanced EGFR-mutant lung cancer that has stopped responding to previous treatments. About 344 adults with this specific type of…

This study tests whether adding the immunotherapy drug durvalumab to standard radiation therapy can help control early-stage non-small cell lung cancer that cannot be surgically removed. About 724 adults with stage I or II lung cancer will receive either durvalumab or a placebo a…

This study follows 192 adults with chronic lymphocytic leukemia (CLL) in Spain who started taking acalabrutinib as their first treatment or switched to it due to side effects from an older drug. Researchers will track how many patients stay on the therapy after 24 months and look…

This phase 3 study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps keep high-risk bladder cancer from coming back. About 1,000 adults with non-muscle-invasive bladder cancer who have not had BCG before will be randomly assigned to get either…

This study tests a combination of two drugs, capivasertib and fulvestrant, in people with a certain type of advanced breast cancer (HR+/HER2-) that has gotten worse after standard hormone therapy and a CDK4/6 inhibitor. The goal is to see how long it takes before patients need an…

This study tested two immunotherapy drugs (durvalumab and tremelimumab) alone or together against standard chemotherapy for people with advanced non-small-cell lung cancer who had not received prior treatment. Over 1,100 participants worldwide were enrolled. The goal was to see i…

This study tests a new drug called datopotamab deruxtecan (Dato-DXd) combined with immunotherapy, with or without carboplatin, in people with advanced or metastatic non-small cell lung cancer (NSCLC). The goal is to see if the combination is safe and helps shrink tumors. About 15…

This study tests whether a daily pill called olaparib can help prevent breast cancer from returning in people with inherited BRCA1 or BRCA2 gene mutations who have already completed surgery and chemotherapy. About 1,800 participants with high-risk, HER2-negative breast cancer rec…

This study is testing an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors like ovarian, breast, pancreatic, and prostate cancer. The goal is to see if the drug is safe and tolerable when given alone or with other cancer treatments. About 70…

This study tests whether the targeted drug osimertinib can prevent early-stage lung cancer from coming back after complete surgical removal. About 390 adults with a specific genetic mutation (EGFR) and stage IA2-IA3 non-small cell lung cancer will receive either osimertinib or a …

This study tests a new drug, savolitinib, against a standard treatment, sunitinib, for people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib works better at slowing cancer growth and to check its …

This study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) works better than osimertinib alone for people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. About 587 adults with newly diagnosed or recurrent advanced lun…

This study tests a new drug called AZD7798 in 120 adults with moderate to severe Crohn's disease, a condition that causes inflammation in the digestive tract. Participants receive either the drug or a placebo to see if it reduces symptoms like diarrhea and abdominal pain, and imp…

This study follows about 90 adults with chronic lymphocytic leukemia (CLL) who are taking the drug acalabrutinib as part of their normal care. Researchers will collect information from medical records to see how long patients live without their cancer getting worse and what side …

This study tests if a new drug, benralizumab, works better than an existing one, mepolizumab, for people with a rare disease called EGPA that causes inflammation in blood vessels. About 140 adults with active EGPA will receive either drug for 52 weeks, and researchers will check …

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with advanced solid tumors that have certain HER2 gene mutations and have stopped responding to other treatments. The goal is to see if the drug can shrink tumors. About 102 adults with various cancer types (…

This study tests whether a newer drug, trastuzumab deruxtecan (T-DXd), given alone or with other drugs before surgery, works better than the standard treatment for people with high-risk HER2-positive early breast cancer. About 927 adults will take part. The main goal is to see if…

This study offers continued treatment with durvalumab to cancer patients who have already completed a previous study and are still benefiting from the drug, as judged by their doctor. About 214 participants will be enrolled to monitor safety and side effects over time. The goal i…

This study tests a combination of two drugs, capivasertib and fulvestrant, in Chinese patients with advanced or metastatic HR+/HER2- breast cancer that has returned or worsened after hormone therapy. About 258 participants will receive the treatment to see if it delays the need f…

This study tests an investigational drug called tozorakimab in adults with symptomatic COPD who have had at least two moderate or one severe flare-up in the past year and have high levels of eosinophils (a type of white blood cell). Participants receive either tozorakimab or a pl…

This study tests whether taking osimertinib for 5 years after surgery can stop EGFR-mutant lung cancer from coming back. About 188 adults with stage II-IIIB non-small cell lung cancer who had their tumor fully removed will take the drug daily. The main goal is to see how long the…

This study follows 155 people with severe asthma who are starting a new medicine called tezepelumab. Researchers want to see how well it controls asthma symptoms and improves quality of life over two years in real-world clinics across Greece. The goal is to understand if this tre…

This study tests a drug called anifrolumab for people with lupus-related skin rashes that haven't improved with standard treatments. About 306 adults will receive either the drug or a placebo to see if it reduces rash severity by 70%. The goal is to control the disease, not cure …

This study tests two new drug combinations for people with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. About 712 participants will receive either a combination of three drugs (durvalumab, tremelimumab, and enfortumab vedotin) or two dr…

This study tests a combination of two drugs, ceralasertib and durvalumab, in adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The goal is to see if the combination can shrink tumors and …

This study follows 1620 lupus patients who are not responding well to current treatments to see how safe and effective Saphnelo (anifrolumab) is over the long term. Researchers will monitor for side effects like infections and allergic reactions. The goal is to gather real-world …

This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) with or without a targeted therapy (lenvatinib) to a standard procedure called TACE can help people with liver cancer that cannot be surgically removed. About 760 participants will be randomly a…

This study tests a new injectable drug, anifrolumab, for adults with moderate-to-severe systemic lupus erythematosus (SLE) who are already on standard treatments. The goal is to see if adding anifrolumab can better control lupus activity and reduce flare-ups. About 367 participan…

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other cancer medicines in people whose breast cancer has spread and has low levels of a protein called HER2. The main goals are to see if the combinations are safe and to find the best doses. About 138 ad…

This study tested whether adding another targeted drug (ceralasertib or adavosertib) to olaparib works better than olaparib alone for people with metastatic triple-negative breast cancer. Participants had specific gene changes (HRR-related, including BRCA). The trial aimed to see…

This study looks at whether a standardized treatment plan can help chronic kidney disease patients with high potassium levels (hyperkalemia) better control their condition and optimize their medications. About 1,000 adults with kidney disease and high potassium will follow a guid…

This study tests an investigational drug called tozorakimab in about 1,450 adults with symptomatic COPD who have had at least two moderate or one severe flare-up in the past year. Participants must already be on standard inhaled therapy. The main goal is to see if the drug can re…

This study is for people with advanced hormone-positive, HER2-negative breast cancer that has a specific gene change (ESR1 mutation). Participants currently stable on standard therapy will either switch to a new oral drug (AZD9833) plus a CDK4/6 inhibitor or stay on their current…

This study tests if tezepelumab, a monthly injection, can help people with severe asthma safely reduce their daily maintenance inhaler (SYMBICORT) while still keeping their asthma under control. About 326 adolescents and adults will be followed for up to 72 weeks. The goal is to …

This study tests a combination of three drugs (durvalumab, tremelimumab, and lenvatinib) as the first treatment for people with advanced liver cancer that cannot be removed by surgery. About 114 participants will receive the drugs to see if they can slow cancer growth and improve…

This phase 3 study tests whether adding capivasertib to fulvestrant can slow the growth of advanced or metastatic HR+/HER2- breast cancer in people whose cancer worsened after aromatase inhibitor treatment. About 818 adults are enrolled. The main goal is to see how long the cance…

This study tests whether a targeted drug called acalabrutinib works better than a standard combination of chemotherapy (chlorambucil) and an antibody (rituximab) for people with untreated chronic lymphocytic leukemia (CLL). About 155 adults aged 65 or older (or younger with certa…

This study tests whether combining two immunotherapy drugs, durvalumab and oleclumab, can help people with advanced lung cancer that hasn't spread after initial chemoradiation. About 30 adults with stage III non-small cell lung cancer will receive the drug combo. The main goal is…

This study tests the drug dapagliflozin in 731 Chinese adults with chronic kidney disease to see if it can slow kidney function decline and reduce complications. Participants take the drug alongside their current treatments. The goal is to gather safety and effectiveness data for…

This study tests whether adding new cancer drugs to the immunotherapy durvalumab, with or without chemotherapy, can safely control advanced lung cancer. It involves 175 adults with stage IV non-small cell lung cancer who have not had prior treatment for their metastatic disease. …

This study tests a drug called trastuzumab deruxtecan (T-DXd) against standard treatments for people with advanced non-small cell lung cancer that has a specific genetic change (HER2 mutation). About 454 adults who have not had prior treatment for their advanced cancer will be ra…

This study tested two immunotherapy drugs (durvalumab alone or combined with tremelimumab) against standard chemotherapy in over 1,100 people with stage IV bladder cancer that could not be removed by surgery. The goal was to see if these treatments helped people live longer. The …

This study tests a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers. The drug works by blocking a protein that helps cancer cells grow. The main goal is to check safety and side effects, and to see how well the drug works. About 35 people will take …

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that has spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug…

This study looks at whether changing the rescue inhaler from albuterol alone to albuterol plus budesonide can lower the number of severe asthma attacks. About 1,500 adults with asthma who have had at least one severe attack in the past year will switch to the new inhaler. Researc…

This study checks if a new version of a common asthma inhaler works just as well as the current one. About 422 adults with asthma will use both inhalers and a placebo to compare lung function. The goal is to make sure the new propellant is safe and effective.

This study tests a combination of drugs (durvalumab, chemotherapy, and olaparib) as a first treatment for people in Spain with advanced or recurrent endometrial cancer that has a specific genetic marker (pMMR). The goal is to see if the treatment is safe and helps control the can…

This study tests an artificial intelligence (AI) tool that analyzes chest X-rays to give a lung nodule malignancy score, predicting the risk of lung cancer. Researchers will compare the AI's score with CT scan results from 712 adults aged 35 and older who have a lung nodule. The …

This study looks at how well tezepelumab works for people aged 12 and older with severe asthma in Russia. Over 52 weeks, researchers track changes in asthma control and symptoms using patient questionnaires. The goal is to understand the real-world benefits of this treatment for …

This study is not testing a new treatment. Instead, it will collect information from about 6,000 adults with chronic lymphocytic leukemia (CLL) in Russia to see how doctors currently manage the disease. Researchers will look at patient health records, genetic test results, and tr…

This study was designed to track severe flare-ups (exacerbations) in people with COPD in Egypt, aiming to understand how often they happen and how they affect patients' health and healthcare use. It planned to look back at medical records from the previous three years. However, t…

This study tracks 274 adults with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). It looks at how well the drug osimertinib works when used as the first treatment in real-life settings, not just in controlled trials. Researchers will follow pa…

This study looks at how common BRCA1/2 gene mutations are in people with high-risk early breast cancer that is HER2-negative. It also tracks what treatments they receive and how they do over time. About 625 adults in Russia who have already had surgery will take part, and no new …

This study looks at how a new drug called AZD5004 changes the way the body processes two diabetes medications, mitiglinide and pioglitazone. It involves 32 healthy volunteers and is not meant to treat any disease. The goal is to gather safety and drug-level information for future…

This early-phase study looks at how the antibiotic rifampicin changes the way the body handles the experimental cancer drug cediranib. It involves 64 adults with advanced solid tumors that have not responded to standard treatments. The goal is to understand drug interactions, not…

This study follows about 1,200 people with myasthenia gravis (MG) in China to understand how the disease is treated and how patients feel over time. Researchers will collect information on symptoms, daily activities, quality of life, and treatments every 6 months until 2027. The …

This study tests whether a single tablet containing two drugs (laroprovstat and rosuvastatin) works as well as taking each drug separately. It involves 44 healthy adults aged 18 to 55 who will receive both the combination and individual tablets at different times. The goal is to …

This study tests two different oral forms of the drug AZD2281 in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form, not to cure the cancer. About 197 participants will receive both forms i…

This study watches 350 people with chronic lymphocytic leukemia (CLL) who are taking the drug acalabrutinib as part of their normal care. Researchers want to see how long patients stay on the drug, why they stop, and how well it works outside of a strict research setting. The goa…

This study looks at how a new medicine called AZD6793 changes the way metformin (a common diabetes drug) works in the body. Researchers want to see if AZD6793 affects blood sugar levels and how much metformin stays in the blood. The study was planned for 28 adults with type 2 dia…

This study looks at whether educating doctors in small and mid-sized city hospitals about standard guidelines helps improve testing and treatment for people with advanced non-small cell lung cancer. About 1000 patients will be observed to see if more get the right molecular tests…

This study watches over 800 heart failure patients in Germany who are starting dapagliflozin, a drug recently approved for heart failure. Researchers will track how long patients stay on the drug, any side effects, and changes in symptoms and quality of life. The goal is to see h…

This study looks at 250 adults with chronic lymphocytic leukemia (CLL) in Romania who are taking the drug acalabrutinib as part of their normal care. Researchers want to see how long patients stay on the treatment and why they might stop. The goal is to understand how the drug wo…

This study watches how Chinese patients with a rare kidney condition called aHUS are treated in everyday medical practice. It includes both children and adults, and follows them for up to 12 months to see how they do. The goal is to learn more about the disease and its management…

This study monitors the safety of selumetinib in children aged 3 to 18 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable tumors. Researchers will track heart function, bone growth, muscle enzymes, liver health, eye problems, and puberty development over time. T…

This early-stage study is testing a new drug, AZD0292, in 18 healthy Japanese adults to see if it is safe and how the body processes it. Participants receive a single dose of the drug or a placebo by IV. The main goal is to check for side effects and measure drug levels in the bl…

This study will gather information from 5,000 adults with chronic kidney disease (CKD) to see how the disease progresses and how it is currently treated. Researchers want to find gaps between real-world care and medical guidelines, and build a model to predict which patients are …

This study tracks 250 adults with advanced non-small cell lung cancer in Russia who are receiving the drug durvalumab as part of their routine care. The goal is to see how safe and effective the treatment is outside of a controlled clinical trial, and to understand how long patie…

This study in 8 healthy men aged 30-65 tracks how the investigational drug AZD4144 is absorbed, broken down, and eliminated from the body. Participants receive a single dose either by mouth or injection, with a tiny radioactive label to follow the drug. The goal is to understand …

This study watches 315 people with severe asthma in Italy who are starting a new drug called tezepelumab. Researchers will track their health, asthma attacks, and other conditions for up to two years. The goal is to see how well the drug works in real life, not just in a lab.

This early-stage study looks at how the experimental drug saruparib affects other medications in people with advanced solid tumors that have not responded to standard treatments. About 41 participants will take saruparib along with common drugs to measure changes in drug levels i…

This study watches how doctors in Russia treat advanced lung cancer in about 1500 patients. It does not test any new medicine or procedure. Instead, researchers collect information on which treatments are used and how often genetic tests are done. The goal is to understand real-w…

This study looks at over 1,500 people in Russia with moderate-to-severe COPD who have frequent lung attacks (exacerbations). Researchers will collect information on their health habits, other illnesses, and current treatments to better understand this group. The goal is to descri…

This study observes 100 adults in Russia who have a rare autoimmune disease called neuromyelitis optica spectrum disorder (NMOSD). Researchers will collect information from medical records and follow-ups to see what treatments doctors use and how patients fare over time. No exper…

This study watches how Chinese asthma patients use biologic medicines and how well they work. About 202 people will be followed for a year while getting their usual care. The goal is to learn about treatment patterns, not to test a new drug.

This study is not testing a new treatment. Instead, it observes how lupus (SLE) is diagnosed, how it changes over time, and what treatments doctors use in routine practice in Kazakhstan. About 509 adults with lupus will be followed to collect information on disease activity, orga…

This study was designed to help doctors better manage serious bleeding in patients taking blood thinners. It planned to include 168 adults in Brazil who were on long-term blood thinners and had a major bleed. The study was withdrawn before enrolling anyone, so no results are avai…

This study observes 137 adults with chronic lymphocytic leukemia (CLL) in Germany who are already prescribed acalabrutinib. Researchers will track how many patients continue taking the drug after 1 and 2 years in routine clinical practice. No experimental treatment is given; the …